Verapamil in acute myocardial infarction. The Danish Multicentre Study Group

Abstract

The reasons for starting a trial of verapamil in early intervention of acute myocardial infarction (AMI) are reviewed. In a pilot study of sixty-one patients it was demonstrated that verapamil probably had no harmful effects in patients with AMI. A multicentre study is now in progress in Denmark; 1433 have been included. Patients are treated with either placebo or verapamil 120 mg three times a day for 6 months. The results of the study, that is effect of verapamil treatment on death and reinfarction, will be available in 1982.